Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chattem Acquires “Great Brands” In Wake Of J&J’s Pfizer Purchase

This article was originally published in The Tan Sheet

Executive Summary

Chattem said its past experience with brands such as Icy Hot and Selsun Blue will make for an easier transition of its newest package acquisition
Advertisement

Related Content

Chattem’s Dexatrim Looks For Cost-Conscious Consumers Unfriendly To Alli
Chattem Sales Up 51% Behind Ongoing Push From J&J Acquisitions
Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales
Chattem/J&J deal closes
J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off
Chattem Counts On Extensions Across Core Brands For 2007 Growth
Boehringer Hits Above The Belt With Zantac Purchase
J&J Picks Up Listerine, Nicorette With $16.6 Bil. Purchase Of Pfizer OTCs
J&J Picks Up Listerine, Nicorette With $16.6 Bil. Purchase Of Pfizer OTCs
Chattem Selsun Blue Purchase Provides Entry Into Five New Foreign Markets

Topics

Advertisement
UsernamePublicRestriction

Register

PS099820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel